AIM
ABCL icon

Aigen Investment Management’s AbCellera Biologics ABCL Stock Holding History

Aigen Investment Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,724
Closed -$89.8K – 642
2023
Q4 		$89.8K Sell
15,724
-71,071
-82% -$329K 0.02% 732
2023
Q3 		$399K Buy
+86,795
New +$528K 0.08% 435

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Aigen Investment Management's ABCL Position: Q1 2024 in Review

Aigen Investment Management sold out of AbCellera Biologics (ABCL) in Q1 2024, closing a stake of 15,724 shares — an estimated $89.8K sold.

Aigen Investment Management first reported a position in ABCL in Q3 2023 and held it in 2 quarters. The position peaked at $399K in Q3 2023. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

  • Aigen Investment Management reported no remaining AbCellera Biologics position as of Q1 2024 after selling out during the quarter.
  • Aigen Investment Management sold 15,724 AbCellera Biologics shares in Q1 2024, an estimated $89.8K.
  • Aigen Investment Management first reported a position in AbCellera Biologics in Q3 2023 and held it in 2 quarters.
  • Aigen Investment Management's AbCellera Biologics position peaked at $399K in Q3 2023.
  • 154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on Aigen Investment Management's 13F filing for Q1 2024, filed 14 May 2024.